Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers December 11, 2014

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences December 11, 2014

Syros Pharmaceuticals' Scientists Publish New Method to Detect Epigenomic Changes Following Drug Treatment November 6, 2014

Syros Pharmaceuticals Closes $53 Million Series B Financing October 27, 2014

Syros Pharmaceuticals' Scientific Founders Publish New Research on Gene Control MechanismsOctober 14, 2014

Syros Pharmaceuticals Presents Research on Gene Control in Acute Myeloid Leukemia at AACR Hematologic Malignancies Meeting September 23, 2014

Syros Pharmaceuticals Co-Founders' Novel Approach to Cancer Regulation Published in Nature June 23, 2014

Syros Pharmaceuticals Appoints Genomics Entrepreneur Jorge Conde to Dual Role as Chief Financial Officer and Chief Product Officer June 10, 2014

Richard A. Young, Syros Pharmaceuticals Scientific Founder, to Open AACR Annual Meeting 2014 with Address Highlighting His Pioneering Gene Control Research April 2, 2014

Syros Pharmaceuticals Announces Publication of Important Scientific Studies Related to Company's Industry-Leading Gene Control Platform  December 18, 2013

Dr. Nathanael Gray, a Syros Pharmaceuticals Founder, Honored with 2013 Meyenburg Cancer Research Award  December 16, 2013

Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors   November 21, 2013

Syros Pharmaceuticals Announces New Findings on Central Role of Super-Enhancers in Controlling Cell Biology and Disease   October 10, 2013

Syros Pharmaceuticals Appoints Vicki L. Sato, Ph.D. to Board of Directors   September 5, 2013

Syros Pharmaceuticals Appoints Eric R. Olson, Ph.D. as Chief Scientific Officer   May 22, 2013

Syros Pharmaceuticals Launches with $30 Million Series A Financing  April 11, 2013

Syros Pharmaceuticals Announces Publications in Cell Related to Key Gene Control Discovery  April 11, 2013

Media Contact:

Dan Quinn | Ten Bridge Communications Inc | 781.475.7974 | email: